AgomAb Therapeutics' Drug in the FDA Approval Process
This section highlights FDA-related milestones and regulatory updates for drugs developed by AgomAb Therapeutics (AGMB).
Over the past two years, AgomAb Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
Ontunisertib. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Ontunisertib FDA Regulatory Timeline and Events
Ontunisertib is a drug developed by AgomAb Therapeutics for the following indication: Fibrostenosing Crohn’s Disease.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Ontunisertib
- Announced Date:
- October 13, 2026
- Indication:
- Fibrostenosing Crohn’s Disease
Announcement
Agomab Therapeutics NV announced that the first patient has been dosed in NOV-ERA, the Company's global Phase 2b study evaluating ontunisertib in patients with symptomatic FSCD.
AI Summary
Agomab Therapeutics NV announced that the first patient has received treatment in NOV-ERA, a global Phase 2b study of ontunisertib for adults with symptomatic fibrostenosing Crohn’s disease (FSCD). The trial is expected to enroll about 320 patients. It is randomized, double-blind, and placebo-controlled, meaning participants and researchers will not know who receives the drug or placebo during the study.
Participants will receive one of three twice-daily doses of ontunisertib—100, 200, or 400 mg—or placebo for 52 weeks. The main goal is to measure how many patients’ narrowed bowel passages can be passed with an endoscope at Week 24. Researchers will also assess safety, imaging results, symptoms, quality of life, and FSCD-related events such as surgery. Agomab says the study will help guide the choice of outcomes for later trials. The company views ontunisertib as a potential targeted treatment for fibrosis, a cause of bowel narrowing. The drug is investigational; its safety and effectiveness have not been established.
Read Announcement- Drug:
- Ontunisertib
- Announced Date:
- October 8, 2026
- Indication:
- Fibrostenosing Crohn’s Disease
Announcement
Agomab Therapeutics NV announced that OLE data of the Phase 2a STENOVA study will be presented in an oral session at United European Gastroenterology (UEG) Week 2026, taking place October 17-20 in Barcelona, Spain.
AI Summary
Agomab Therapeutics NV said data from the open-label extension (OLE) of its Phase 2a STENOVA study will be presented in an oral session at UEG Week 2026, held October 17–20 in Barcelona, Spain. The study examined long-term treatment with ontunisertib in people with symptomatic fibrostenosing Crohn’s disease, a form of Crohn’s disease that causes narrowing of the bowel. Participants received 200 mg twice daily for up to 48 additional weeks after the initial 12-week study period. Of those eligible to continue, 49 joined the extension, and 37 completed it.
The OLE assessed long-term safety and drug levels, and explored disease progression and clinical events. The presentation will include objective imaging assessments. Agomab said the findings support moving ahead with its planned global Phase 2b NOV-ERA study. The company will also host a scientific symposium on how inflammation and fibrosis contribute to bowel damage and potential treatment approaches. Ontunisertib remains investigational; its safety and effectiveness have not been established.
Read Announcement- Drug:
- Ontunisertib
- Announced Date:
- October 1, 2026
- Indication:
- Fibrostenosing Crohn’s Disease
Announcement
Agomab Therapeutics NV announced positive results of the 48-week OLE portion of the Phase 2a STENOVA trial evaluating ontunisertib in patients with FSCD, a severe manifestation of Crohn's disease characterized by progressive bowel fibrosis and intestinal strictures.
AI Summary
Agomab Therapeutics reported positive results from the 48-week open-label extension of its Phase 2a STENOVA trial of ontunisertib in people with fibrostenosing Crohn’s disease, a severe form marked by bowel scarring and narrowing. Of eligible patients, 49 (94%) entered the extension, and 37 completed it. Participants received ontunisertib twice daily alongside standard care, for up to 60 weeks of treatment overall.
The treatment showed a generally favorable safety and tolerability profile. Five serious adverse events occurred in four patients; all were considered unrelated or unlikely to be related to the drug. Researchers also reported low drug levels in the blood, consistent with its gut-focused design.
Only one Crohn’s-related procedure—a balloon dilation—was reported, with no surgeries. This represented a 3% annualized event rate. Imaging suggested that bowel strictures remained stable, while symptoms and disease activity stayed low. At Week 48, 97% of evaluable patients were in clinical remission based on a disease activity score.
Agomab plans to begin the global Phase 2b NOV-ERA trial in the coming months. Ontunisertib remains investigational; its safety and effectiveness have not been established.
Read Announcement- Drug:
- Ontunisertib
- Announced Date:
- June 23, 2026
- Indication:
- Fibrostenosing Crohn’s Disease
Announcement
Agomab Therapeutics NV announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).
AI Summary
Agomab Therapeutics NV has announced the design of its upcoming Phase 2b NOV-ERA study of ontunisertib, an investigational oral, GI-restricted inhibitor of ALK5 for the potential treatment of fibrostenosing Crohn’s disease (FSCD). The study is planned to test three doses of ontunisertib—400 mg, 200 mg, and 100 mg—against placebo in a 1:1:1:1 randomization, with twice-daily dosing.
The trial will include a 6-week screening period, a 52-week treatment period, and a 2-week follow-up. Its main goal is to measure the proportion of patients who achieve endoscopic passability of the ileal index stricture at Week 24, a novel endpoint meant to help show whether the treatment can ease bowel narrowing.
Agomab said the study is intended to help identify endpoints for later registrational trials. First patient dosing is expected in the second half of 2026, and the company notes that ontunisertib is still experimental and has not been proven safe or effective.
Read Announcement
AgomAb Therapeutics FDA Events - Frequently Asked Questions
As of now, AgomAb Therapeutics (AGMB) has not received any FDA approvals for its therapy in the last two years.
In the past two years, AgomAb Therapeutics (AGMB) has reported FDA regulatory activity for Ontunisertib.
The most recent FDA-related event for AgomAb Therapeutics occurred on October 13, 2026, involving Ontunisertib. The update was categorized as "Dose Update," with the company reporting: "Agomab Therapeutics NV announced that the first patient has been dosed in NOV-ERA, the Company's global Phase 2b study evaluating ontunisertib in patients with symptomatic FSCD."
Currently, AgomAb Therapeutics has one therapy (Ontunisertib) targeting the following condition: Fibrostenosing Crohn’s Disease.
More FDA Event Resources from MarketBeat
Companies With Recent FDA Events
FDA Event Stage Terminology & Abbreviation Guide
- NDA: New Drug Application
- ANDA: Abbreviated New Drug Application
- sNDA: Supplemental New Drug Application
- BLA: Biologics License Application
- sBLA: Supplemental Biologics License Application
- FDA Approved: Approved by the FDA
- EMA: European Medicines Agency
- CE Mark: European Union Certification
- NMPA: China National Medical Products Administration
- MHLW: Japanese Ministry of Health
- FDA Meeting: Consultation with FDA
- Pre-IND: Pre-Investigational New Drug Meeting
- Breakthrough Therapy: Special FDA designation for promising therapies
- Fast Track: Accelerated FDA approval pathway
- Orphan Drug: Designation for rare disease treatments
- RPD: Rare Pediatric Disease Designation
- RMAT: Regenerative Medicine Advanced Therapy
- DSMB Review: Data Safety Monitoring Board Review
- IDMC Review: Independent Data Monitoring Committee
- MAA: MHRA Marketing Authorization Application
- RTF: Refusal to File (Rejected Application)
- 510(k): FDA Clearance for Medical Devices
- Rolling Submission: Staggered regulatory review process
FDA progress for NASDAQ:AGMB last updated on 10/14/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.